Skip to main content

Table 1 Baseline characteristics of Metastatic Melanoma Patients receiving Immune Checkpoint Inhibitors

From: The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

  

Normal Weight

Overweight

Obesity

Pvalue

N(%)

Total = 423

139 (33)

165 (39)

119 (28)

 

Age (mean(SD))

62.1(16)

64.5(14)

66(13)

0.09

Gender

Male

75(54)

114(69)

78(66)

0.02

Female

64(46)

51(31)

41(34)

Stage

Stage III

11(8)

14(8)

15(13)

0.38

Stage IV

128(92)

151(92)

104(87)

ICI Treatment

CTLA-4

64(46)

75(45)

61(51)

0.65

PD-1

49(35)

55(33)

41(34)

Combination

26(19)

35(21)

17(14)

ECOG Performance Status

0

93(69)

120(75)

90(80)

0.18

>=1

41(31)

40(25)

23(20)

LDH

Normal

71(62)

97(69)

73(79)

0.02

High

44(38)

44(31)

19(21)

BRAF Mutation

V600

7(8)

9(8)

10(12)

0.06

Other

0(0)

5(4)

0(0)

WT

84(92)

101(88)

74(88)

Number of metastatic sites [mean (SD)]

2.6(1)

2.7(1)

2.3(1)

0.05

Line of TRT

First Line

87(63)

108(65)

77(65)

0.87

Non-First Line

52(37)

57(35)

42(35)

Alive Status

Alive

71(51)

77(47)

59(50)

0.74

Dead

68(49)

88(53)

60(50)

Follow up months [median (range)]

33.1(1.4-121.1)

38.6(2.7-172.2)

37.7(11.0-173.3)

0.52